TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23224510
Drug: Δ(9)-tetrahydrocannabinol (THC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg
Study: 15157730
Drug: Placebo via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via metered-dose inhaler and Aerochamber, twice daily for 2 years
Study: 8503339
Drug: Flutamide 750
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 750 mg/day
Study: 8503339
Drug: Flutamide 375
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 375 mg/day (hormone-treated patients)
Study: 3067610
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of L-carnitine by intravenous infusion
Study: 3067610
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg of ethanol in the form of white wine
Study: 3067610
Drug: L-carnitine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine alone
Study: 26567593
Drug: Anaferon (ultra-high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaferon (ultra-high dilutions of antibodies to human interferon γ), n=20
Study: 16542795
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy radiation therapy (RT)
Study: 16542795
Drug: 10 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Gy radiation therapy (RT)
Study: 16542795
Drug: No flank
Approvals — FDA: no, EMA: no, PMDA: no
Description: No flank radiation therapy (RT)
Study: 12677011
Drug: Intra-arterial pro-urokinase
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial pro-urokinase (r-proUK) treatment
Study: 2277578
Drug: 0.375% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% plain marcaine with 1:200000 epinephrine 10 mL to each side (Group C)
Study: 8610862
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg metoclopramide
Study: 25581426
Drug: Red clover
Normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover (40 mg dried leaves, 2 capsules daily for 12 weeks)
Study: 25581426
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 mg starch, 2 capsules daily for 12 weeks)
Study: 18782497
Drug: Various disease-modifying
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various disease-modifying therapies (DMTs)
Study: 12182252
Drug: IV rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV rosiglitazone 2 mg alone
Study: 12182252
Drug: Oral rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rosiglitazone 4 mg alone
Study: 8562272
Drug: Lacidipine (calcium-antagonist)
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (calcium-antagonist)
Study: 1775608
Drug: Desipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine at 150 mg daily
Study: 6456165
Drug: Neurodevelopmental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental therapy program, three times a week for nine weeks
Study: 31318750
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (635 nm, 15 mW) with standard treatment (rest, icing, compression, elevation)
Study: 31318750
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (rest, icing, compression, elevation)
Study: 28651971
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messaging intervention focusing on anticipated regret and self-monitoring of PMC
Study: 23718743
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate 20 mL/kg
Study: 23718743
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyethyl starch followed by Ringer's acetate
Study: 19454549
Drug: 4‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐mg oral nicotine pouch (Zonnic pouch)
Study: 11463108
Drug: Intramuscular arteether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular arteether (3.2 mg/kg on Day 0, followed by 1.6 mg/kg on Days 1 to 4)
Study: 11463108
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine dihydrochloride (20 mg of the salt/kg, followed by 10 mg of the salt/kg every 8 hr up to Day 6)
Study: 11463108
Drug: Intramuscular arteether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular arteether
Study: 11463108
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine dihydrochloride
Study: 8024164
Drug: Pentoxifylline (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1,200 mg/day)
Study: 8024164
Drug: Buflomedil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil (600 mg/day)
Study: 8351862
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg/day)
Study: 174388
Drug: Ethanol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.5 g/kg)
Study: 12939417
Drug: Topiramate (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (maximum tolerated dose up to 800 mg/day)
Study: 11032270
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 microg) added to ropivacaine (40 ml 0.75%)
Study: 11032270
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 ml) added to ropivacaine (40 ml 0.75%)
Study: 1427457
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered calcium heparin (every 8 h)
Study: 1427457
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered calcium heparin
Study: 27454383
Drug: High-dose AZD9773
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AZD9773
Study: 27454383
Drug: Low-dose AZD9773
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AZD9773
Study: 22971864
Drug: Oral Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Erythromycin (standard dose)
Study: 31810978
Drug: Acetylcholinesterase inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase inhibitors
Study: 19065363
Drug: Gel (Prostin)
Normalized name: Otic Gel
DrugBank: Sepia esculenta bone (DB16562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel (Prostin)
Study: 16132903
Drug: Single-dose lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose lenograstim (10 microg/kg once a day)
Study: 16132903
Drug: Split-dose lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose lenograstim
Study: 9457019
Drug: Late childhood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late childhood treatment
Study: 28285240
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Control)
Study: 6976790
Drug: Di-isopropyl phenol
Normalized name: DI-ISOPROPYL SEBACATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-isopropyl phenol (Diprivan) 2.0 mg kg‐1
Study: 6976790
Drug: Di-isopropyl phenol
Normalized name: DI-ISOPROPYL SEBACATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-isopropyl phenol (Diprivan) <1.75 mg kg‐1
Study: 6976790
Drug: Di-isopropyl phenol
Normalized name: DI-ISOPROPYL SEBACATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-isopropyl phenol (Diprivan) 1.5 - 2.0 mg kg‐1
Study: 6976790
Drug: Di-isopropyl phenol
Normalized name: DI-ISOPROPYL SEBACATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-isopropyl phenol (Diprivan) 2.5 mg kg‐1
Study: 6976790
Drug: Di-isopropyl phenol
Normalized name: DI-ISOPROPYL SEBACATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-isopropyl phenol (Diprivan) (any dose)
Study: 7544554
Drug: Traditional drugs
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drugs (proserine, pituitrin, cerucal)
Study: 2782569
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml water 2 hours before surgery
Study: 2782569
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml water 2 hours before surgery + intramuscular morphine 0.15 mg/kg and promethazine 0.5 mg/kg one hour before operation
Study: 31891295
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg/Acetaminophen 216.7 mg
Study: 28013387
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract (CurraNZ™) 600 mg day‐1
Study: 28013387
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract (CurraNZ™) 900 mg day‐1
Study: 25976576
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100mg, twice a day for eight weeks)
Study: 21300704
Drug: Mild CKD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild CKD (60-90 mL/min/1.73 m²)
Study: 17340897
Drug: Early Loaded
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Loaded (EL) implants
Study: 17340897
Drug: Delayed Loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Loaded (DL) implants
Study: 15003147
Drug: 2 mg/d
Normalized name: Uceris, 2 mg/dose rectal foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/d of haloperidol
Study: 15003147
Drug: 8 mg/d
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/d of haloperidol
Study: 8472980
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 800 mg twice daily
Study: 3814227
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g L-aspartic acid for 7 days
Study: 3814227
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg chlorpromazine + 60 mg diazepam daily
Study: 22852118
Drug: Cephazolin, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephazolin, 1.0 g i.v., once postoperatively
Study: 22852118
Drug: Amoxicillin‐clavulanate, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate, 1000 mg orally for 7 days postoperatively
Study: 16948661
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 1.8 mL
Study: 16948661
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 0.9 mL plus lingual infiltration of 0.9 mL
Study: 9884382
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (r-hirudin) regimen A1 (0.4 mg/kg bolus and then 0.15 mg/kg/h)
Study: 9884382
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (r-hirudin) regimen A2 (0.2 mg/kg bolus and then 0.1 mg/kg/h)
Study: 1892185
Drug: oral ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ritodrine (20 mg every 4 hours)
Study: 30276833
Drug: 60 μg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg of beraprost (three tablets)
Study: 25182454
Drug: Dalteparin subcutaneously
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin subcutaneously twice daily, initial weight-based dosing: infants (< 12 months) 150 IU kg(‐1), children (1‐12 years) 125 IU kg(‐1), adolescents (13‐18 years) 100 IU kg(‐1)
Study: 10421303
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches prescribed by GPs for up to 12 weeks
Study: 10421303
Drug: GP counselling
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP counselling with nicotine-patch treatment
Study: 19542983
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day
Study: 20466589
Drug: Pregabalin 450
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450 mg/day
Study: 16352669
Drug: Acyline (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline (GnRH antagonist) for medical castration
Study: 15303634
Drug: Amoxicillin/clavulanate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 1 g/125 mg three times daily for 10 days
Study: 6737208
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (relaxation exercises)
Study: 31756444
Drug: Higher genetically
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher genetically predicted levels of follicle stimulating hormones
Study: 31756444
Drug: Higher predicted
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher predicted levels of luteinizing hormone
Study: 29845672
Drug: Sodium pentosan
Normalized name: Pentosan Polysulfate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium pentosan polysulfate (Na‐PPS) 50 mg subcutaneously twice daily
Study: 25531109
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose atorvastatin (80 mg)
Study: 25531109
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose atorvastatin (10 mg)
Study: 23436336
Drug: Entocort EC
Normalized name: Entocort EC
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Entocort EC 9 mg
Study: 23398944
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d lutein
Study: 22835510
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d lutein plus 10 mg/d zeaxanthin
Study: 15289993
Drug: Glucose 32.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 32.5 g/200 ml (G32.5)
Study: 15289993
Drug: Glucose 75
Normalized name: glucose 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 75 g/200 ml (G75)
Study: 12170197
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy after PTA
Study: 2132289
Drug: Paracetamol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (10 ml syrup equivalent to 500 mg tid)
Study: 31358022
Drug: Cereal containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal containing 4 g β-glucan
Study: 31358022
Drug: Capsulated Lactobacillus
Normalized name: LACTOBACILLUS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsulated Lactobacillus rhamnosus HN001 and cereal containing 4 g β-glucan
Study: 28767288
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) consolidation with reduced doses of anthracyclines
Study: 23642147
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injections (0.1 to 0.3 millilitres)
Study: 21859657
Drug: 1.10 g/kg·d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.10 g/kg·d
Study: 21859657
Drug: 1.02 g/kg·d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.02 g/kg·d
Study: 17084844
Drug: Intranasal E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2/NET 175 microg/275 microg
Study: 12575586
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) combined with Antike capsule (AC)
Study: 9406491
Drug: Green prescription
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green prescription (written exercise advice)
Study: 3369751
Drug: Albuterol aerosol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol, 200 micrograms via Aerochamber
Study: 23443608
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of 0.5 Gy
Study: 23443608
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of 1.0 Gy
Study: 20719808
Drug: Computer-administered version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered version of the Word Memory Test (WMT)
Study: 15671107
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg 17beta‐estradiol (ET)
Study: 12906976
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg for 6 weeks
Study: 10496712
Drug: r‐ProUK 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐ProUK 2 mg/hr
Study: 10496712
Drug: r‐ProUK 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐ProUK 4 mg/hr
Study: 1682735
Drug: Reticulin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reticulin antibodies
Study: 1682735
Drug: Gliadin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliadin antibodies
Study: 1682735
Drug: Follow-up of
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up of reticulin-antibody-positive relatives
Study: 1682735
Drug: Genetic comparison
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic comparison of reticulin-antibody-positive relatives
Study: 1682735
Drug: Genetic comparison
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic comparison of gliadin-antibody-positive relatives
Study: 25433040
Drug: Ciclosporin (1-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (1-5 mg/kg/day) plus steroids
Study: 25433040
Drug: MTX (15-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (15-25 mg weekly) plus steroids
Study: 25433040
Drug: Ciclosporin/MTX combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin/MTX combination therapy plus steroids
Study: 25433040
Drug: Steroids alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids alone (placebo control)
Study: 7687978
Drug: 90 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/m2 of levamisole for 45 days, together with 10 MU/m2 of interferon‐alpha‐2a, three times a week for 6 months (group 2, n = 18)
Study: 20630640
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of Twinrix (720 ELISA units of inactivated hepatitis A virus and 20 μg of purified hepatitis B virus surface antigen) and Engerix-B (20 μg) at 0, 1, and 6 months plus Engerix-B, 40 μg, at month 2
Study: 7907348
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of ranitidine (6.25 mg/hr)
Study: 7907348
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous infusions of famotidine (20 mg every 12 hours)
Study: 22727870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (matched children prior to treatment)
Study: 20706875
Drug: Placebo adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adherence (≥75% of prescribed study medication)
Study: 15215814
Drug: Zofenopril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (15 to 30 mg/d; n = 48)
Study: 15215814
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/d; n = 48)
Study: 9441266
Drug: Parenteral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotic + oral ciprofloxacin sequential therapy (group B)
Study: 9441266
Drug: Parenteral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotics only (group A)
Study: 26193126
Drug: Isoniazid Preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid Preventive Therapy (IPT)
Study: 18491582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lisinopril and Amlodipine
Study: 11221291
Drug: Barnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine (10 or 20 mg/day)
Study: 8706770
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 1.0 mg b.i.d. for 3.5 days (seven doses)
Study: 8706770
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 0.8 mg b.i.d. for 3.5 days (seven doses)
Study: 18415635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received identical volumes of 0.9% NaCl solution
Study: 30559105
Drug: Molidustat (variable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molidustat (variable doses after switching from darbepoetin)
Study: 30559105
Drug: Molidustat (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molidustat (75 and 150 mg after switching from epoetin)
Study: 27183299
Drug: MPH XR-ODT
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH XR-ODT (optimized dose)
Study: 19187079
Drug: Idraparinux 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux 2.5 mg once-weekly subcutaneously
Study: 7951476
Drug: Smoking four
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking four 0.8 mg nicotine cigarettes
Study: 7951476
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of 200 mg of caffeine